Understand heart failure treatment options: A clinical overview of medicines, devices, and advanced care

How heart failure treatment is determined

Heart failure is a clinical syndrome in which the heart cannot meet the body’s demands because of low cardiac output, elevated filling pressure, or both. Treatment begins with identifying the cause and assessing symptoms, heart structure, pumping function, blood tests, and imaging such as echocardiography. Common contributing conditions include coronary artery disease, high blood pressure, valve disease, diabetes, kidney disease, and abnormal heart rhythms. The treatment plan therefore differs substantially between individuals. 1

Clinicians commonly distinguish heart failure with reduced ejection fraction, often called HFrEF, from heart failure with preserved ejection fraction, or HFpEF. HFrEF involves weaker contraction, while HFpEF generally involves a stiff heart that cannot fill normally despite relatively preserved pumping strength. Chronic disease may be stable or may suddenly worsen into acute decompensated heart failure, with increasing breathlessness, swelling, or congestion. Severity and functional limitation help determine whether routine treatment, specialist review, or advanced care is appropriate. 2

Core medicines for reduced ejection fraction

For many people with HFrEF, guideline-directed medical therapy uses several complementary medication groups. The main categories include an angiotensin receptor-neprilysin inhibitor, or ARNI, or an ACE inhibitor or ARB when an ARNI is unsuitable; an evidence-based beta blocker; a mineralocorticoid receptor antagonist; and a sodium-glucose cotransporter-2 inhibitor, known as an SGLT2 inhibitor. These therapies target different biological pathways and are generally introduced and adjusted according to blood pressure, kidney function, potassium levels, heart rate, and tolerance. 3

Medication management requires ongoing review rather than a single prescription decision. Beta blockers are used in selected stable patients and may include carvedilol, bisoprolol, or metoprolol preparations. ARNIs, ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and other medicines can affect kidney function, blood pressure, or electrolytes, so monitoring is important. SGLT2 inhibitors can benefit many people with heart failure whether or not diabetes is present. Adherence, timely prescription renewal, and recognition of adverse effects are part of safe long-term treatment. 3

Managing congestion and preserved ejection fraction

Loop diuretics, such as furosemide, help remove excess fluid and sodium. They can reduce leg swelling, abdominal fluid accumulation, lung congestion, and breathlessness, making them particularly important when a person is retaining fluid. Their principal role is symptom and volume control rather than a demonstrated reduction in mortality. Dosing must be individualized because both persistent congestion and excessive diuresis can impair comfort, blood pressure, kidney function, and the ability to tolerate other heart-failure medicines. 5

HFpEF treatment focuses heavily on controlling congestion and addressing the conditions that worsen filling pressure or cardiovascular risk. SGLT2 inhibitors are now recognized as an important treatment option for many people with HFpEF and HFmrEF, or mildly reduced ejection fraction. Management may also include blood-pressure control, treatment of atrial fibrillation, and attention to obesity, diabetes, kidney disease, and sleep apnea. Other medicines, including selected ARNIs or mineralocorticoid receptor antagonists, may be considered for particular patient groups. 6

Daily self-management and follow-up

Self-management supports, but does not replace, prescribed treatment. Practical measures can include monitoring body weight, following an individualized fluid plan, limiting excess sodium, taking medicines consistently, and remaining physically active at a level considered appropriate by the clinical team. Weight trends may help identify fluid accumulation before symptoms become severe, although a change must be interpreted alongside swelling, breathlessness, appetite, and other findings. Diet and activity advice should account for kidney function, frailty, blood pressure, and other medical conditions. 1

Regular follow-up is needed because heart failure can change over time and treatment doses often require gradual adjustment. Patients should receive clear information about medication adherence, adverse effects, prescription renewal, and when to contact a clinician. Increasing breathlessness, rapidly worsening swelling, fainting, chest pain, or a sudden decline in exercise tolerance can indicate deterioration and requires medical assessment. Heart failure care also addresses smoking, coronary disease, high blood pressure, diabetes, valve disease, and rhythm disorders that may drive progression. 2

Implanted devices and procedures

Medicines are not the only treatment option. An implantable cardioverter-defibrillator may be considered for selected people whose ejection fraction remains substantially reduced despite appropriate medical treatment, particularly when the risk of life-threatening ventricular rhythm disturbances is elevated. The device can detect certain dangerous rhythms and deliver an electrical therapy. Eligibility depends on factors such as ejection fraction, symptoms, duration of optimized treatment, overall health, and expected benefit, so device decisions require specialist assessment rather than symptoms alone. 4

Cardiac resynchronization therapy is another option for selected patients with reduced ejection fraction, persistent symptoms, and electrical conduction delay that causes the ventricles to contract out of sequence. A pacing system can coordinate ventricular contraction and may improve symptoms and outcomes in appropriate candidates. Procedures may also target the underlying cause, including coronary artery disease or valve disease, when restoring blood flow or correcting a mechanical problem is clinically suitable. Device implantation carries procedural risks and requires continuing checks, battery management, and medical follow-up. 2

Advanced heart failure and treatment limitations

Some people develop advanced heart failure despite medication, self-management, and device therapy. Persistent symptoms, repeated hospitalizations, worsening kidney function, low blood pressure, or inability to tolerate guideline-directed medicines can prompt referral to an advanced heart-failure center. Specialist teams evaluate whether mechanical circulatory support, such as a left ventricular assist device, or heart transplantation is appropriate. These therapies involve extensive assessment, ongoing medical supervision, complications, and eligibility criteria related to overall health and clinical goals. 2

Heart failure treatment is not uniform, and no medicine or device is suitable for every patient. Kidney impairment, abnormal potassium, low blood pressure, frailty, pregnancy considerations, medication interactions, and the cause of heart failure can restrict choices or require slower dose changes. Treatment goals may emphasize longer survival, fewer hospitalizations, improved daily function, symptom relief, or comfort-focused and palliative care. Shared decisions should weigh expected benefits, risks, monitoring demands, and the person’s preferences with a qualified healthcare professional. 1

Sources

1. NICE Clinical Guidelines, Chronic heart failure in adults: diagnosis and management, NCBI Bookshelf
2. Merck Manual Professional Edition, Chronic Heart Failure
3. Merck Manual Professional Edition, Medications for Heart Failure
4. Johns Hopkins Medicine, Congestive Heart Failure: Prevention, Treatment and Research
5. The Cardiology Advisor, Heart Failure Management: Current Approaches, Future Directions
6. Springer Nature, Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction